Clinical Trial Update: An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating NNC 0151-0000-0000 for systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• NNC 0151-0000-0000

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Systemic Lupus Erythematosus | Phase 1 | Status: WITHDRAWN